The European Medicines Agency (EMA) has issued its updated Reflection Paper on the Qualification of Non‑Mutagenic Impurities (2026), providing a clearer and more structured framework for evaluating the safety of non‑mutagenic impurities (NMIs) in chemically synthesised pharmaceuticals. This updated guidance applies when NMI levels exceed ICH Q3A/Q3B qualification thresholds, either because new impurities appear or known impurities increase to higher levels.

1) A step‑wise, risk‑based assessment framework

One of the key advancements in the 2026 update is the introduction of a step‑wise, risk‑based assessment approach for impurity qualification:

Determine whether the impurity is already qualified:
EMA now explicitly instructs assessors to first determine whether an impurity is already covered by existing metabolite data or can be considered API‑like based on structure and toxicological relevance.
Conduct a formal Level of Concern (LoC) analysis: A new two‑stage assessment (initial triage + final judgement) determines the need for additional data. This assessment integrates dose, exposure duration, patient population, route of administration, and physicochemical properties, ensuring decisions reflect realistic exposure.
Apply New Approach Methodologies (NAMs): Before considering any in vivo study, risk assessors must apply NAMs, including QSAR, read‑across, and in vitro assays. Only when all scientifically valid non‑animal approaches have been exhausted, or are insufficient, should in vivo studies be considered.

2) Greater emphasis on non‑animal methods

The 2026 revision places significantly more emphasis on modern, non‑animal toxicological methods, expanding expectations related to:

QSAR model suitability and validation
Tools must have a clear endpoint definition, defined applicability domain, and mechanistic plausibility.
Structured read‑across justification
EMA now outlines criteria for chemical similarity, toxicophore analysis, pharmacokinetic alignment, and data reliability, moving away from generic justification approaches.
Integration of in vitro systems
Targeted in vitro assays, microphysiological systems, and mechanistic data (e.g., Adverse Outcome Pathways, AOPs) support impurity-specific risk characterisation.
Encouragement of QIVIVE (Quantitative In Vitro–In Vivo Extrapolation)
Where feasible, QIVIVE helps convert in vitro findings into human-relevant exposure estimates.

3) Modernised, exposure‑based evaluation concepts

EMA’s update aligns impurity qualification with actual patient exposure, introducing:

Route‑specific Threshold of Toxicological Concern (TTC) values
Earlier guidance referenced generic TTCs; the 2026 revision clarifies TTC applicability across oral, dermal, inhalation, and parenteral routes.
New Acceptable Level (AL) calculation
ALs are derived using well‑defined assessment factors (AF1–AF7), accounting for uncertainties such as species differences, variability, exposure duration, effect severity, and read‑across confidence. This modernises risk assessment beyond simple % impurity limits.
Clear criteria for when an in vivo study is scientifically justified
EMA emphasises that animal studies should only be performed when necessary, in line with 3Rs principles. When required, studies must be conducted using the neat impurity, include multiple dose groups, incorporate toxicokinetics, and be designed for robust interpretation.

How Agirad can help

Agirad provides scientific and regulatory expertise to help pharmaceutical manufacturers implement the updated EMA (2026) expectations for NMIs. We translate a complex, modern framework into clear, defensible, submission‑ready impurity justifications.

Gap Analysis — Upgrade impurity dossiers to meet EMA 2026 expectation
NMI Risk Assessment — Impurity‑specific justification (AL, read‑across, exposure).
Study Oversight — CRO selection │ protocol design │ study monitoring │ regulatory‑ready outputs.

Understanding EMA (2026) Reflection Paper on the Qualification of Non Mutagenic Impurities (NMI)

Questions?

Other news